# Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.

> **NCT03540407** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 66 (estimated)

## Conditions studied

- Cervical Carcinoma Stage II
- Cervical Carcinoma Stage III
- Cervical Carcinoma Stage IV
- Endometrial Adenocarcinoma Stage II
- Endometrial Adenocarcinoma Stage III
- Endometrial Adenocarcinoma Stage IV

## Interventions

- **DIETARY_SUPPLEMENT:** Oncoxin-Viusid®
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03540407
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-07
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-09-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540407, "Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03540407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*